Most of the reported drugs were designed to target the interaction of EFNA1-EPHA2 and overlooked other possibilities, we therefore performed molecular docking to screen for molecules directly binding to EFNA1 and examined the anti-tumor activity in ESCC. The gene discussed is EPHA2; the disease is neoplasm.